The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I trial of talimogene laherparepvec for the treatment of peritoneal surface malignancies (TEMPO).
 
John H. Stewart
Consulting or Advisory Role - AmunBio
Research Funding - Amgen
 
Melissa Lowe
No Relationships to Disclose
 
Andrew G Chapple
Research Funding - Merck; Novo Nordisk
 
Donna Niedzwiecki
No Relationships to Disclose
 
Ashley Moyer
Employment - Almac Group (I); Duke University
Research Funding - Duke University
 
Emily Bolch
No Relationships to Disclose
 
Shannon Diane MacLaughlan
No Relationships to Disclose
 
Edward A. Levine
No Relationships to Disclose
 
Omeed Moaven
No Relationships to Disclose
 
Niharika Nettu
No Relationships to Disclose
 
John H Strickler
Stock and Other Ownership Interests - Triumvira Immunologics, Inc
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Bayer; Beigene; Daiichi Sankyo/Astra Zeneca; GlaxoSmithKline; Janssen Oncology; Jazz Pharmaceuticals; Lilly; Merck; Natera (Inst); Pfizer; Roche/Genentech; Seagen; Taiho Oncology; Takeda
Research Funding - A*STAR (Inst); Abbvie (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); BeiGene (Inst); Curegenix (Inst); Daiichi Sankyo/Lilly (Inst); Erasca, Inc (Inst); GlaxoSmithKline (Inst); Leap Therapeutics (Inst); Lilly (Inst); Roche/Genentech (Inst); Seagen (Inst)
Expert Testimony - Seagen
Travel, Accommodations, Expenses - Seagen
 
Dan G. Blazer
No Relationships to Disclose